Pakistan Blocks Import Of Competing Drugs From India
This article was originally published in PharmAsia News
The government of Pakistan has canceled plans to allow 400 drugs to be imported from India, apparently giving in to the nearly $2 billion Pakistan drug industry. Pakistan's Commerce Ministry had planned the imports to forestall a large increase in the prices of life-saving drugs, in some cases by as much as 40 percent. Pakistan's new prime minister reportedly issued orders blocking importation of any drugs that would compete with Pakistani-made drugs and demanded justification for proposals to import 13 vaccines and some cancer drugs not produced in Pakistan. (Click here for more
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.